clinical trial · NCT07157774
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Eli Lilly and Company·phase3·recruiting·n = 10,450
Elevated Lp(a)Atherosclerotic Cardiovascular Disease (ASCVD)MuvalaplinPlacebo
brief summary
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
started
Sep 2, 2025
primary completion
Mar 1, 2031
completion
Mar 1, 2031
last updated
Apr 20, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol